Date: 2014-05-28
Type of information: Collaboration agreement
Compound:
Company: Roche (Switzerland) 20/20 HealthCare Partners (USA - MA)
Therapeutic area: Cancer - Oncology - CNS diseases - Infectious diseases - Inflammatory diseases - Ophthalmological diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On May 28, 2014, 20/20 HealthCare Partners LLC (20/20 HCP), a global investment group focused on early stage medical technology and life science innovation,has announced an agreement with Roche, in which they will source and identify novel treatments and/or technologies in the biotech arena. These areas include oncology/immuno-oncology, neurology, infectious diseases, inflammation and ophthalmology. The partnership aims to advance any identified technologies by facilitating collaborations or the formation of new life science companies. To enhance its relationships with the targeted institutions and to aid in the successful formation of new life science companies, 20/20 HCP has contracted with pharmaceutical and life sciences industry professional Christine Bunt as a 20/20 HCP Venture Partner. Her extensive experience includes the formation and leadership of two life science companies, leading worldwide commercialization for treatments and holding R&D and business development roles with major pharmaceutical companies. Ms. Bunt will lead efforts and serve as a liaison between 20/20 HCP and Roche.
Financial terms:
Latest news:
